Bassam Ghabach
Overview
Explore the profile of Bassam Ghabach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Narra K, Ghabach B, Athipatla V, Blackwell J, Teigen K, Bullock J, et al.
Clin Lung Cancer
. 2024 Sep;
26(2):83-92.
PMID: 39304363
Introduction: Advances in the testing and treatment of patients with non-small cell lung cancer (NSCLC) harboring oncogenic drivers have improved outcomes. Little is known about testing and treatment patterns in...
2.
Lu Y, Meadows R, Gehr A, Narra K, Bullock J, Ghabach B, et al.
Ann Epidemiol
. 2024 Jun;
96:66-72.
PMID: 38914249
Background: Randomized controlled trials (RCTs) suggested breast conserving therapy (BCT) and mastectomy have similar survival for early-stage breast cancer, whereas observational studies reported survival advantage for BCT. We aimed to...
3.
Ojha R, Lu Y, Narra K, Meadows R, Gehr A, Mantilla E, et al.
JCO Clin Cancer Inform
. 2023 Jun;
7:e2300001.
PMID: 37343196
Purpose: Decision support tools (DSTs) to facilitate evidence-based cancer treatment are increasingly common in care delivery organizations. Implementation of these tools may improve process outcomes, but little is known about...
4.
Lu Y, Gehr A, Anikpo I, Meadows R, Craten K, Narra K, et al.
Breast Cancer Res Treat
. 2022 Aug;
195(3):401-411.
PMID: 35971056
Purpose: Evidence of cardiotoxicity risk related to anthracycline or trastuzumab exposure is largely derived from breast cancer cohorts that under-represent socioeconomically marginalized women, who may be at increased risk of...
5.
Lu Y, Gehr A, Meadows R, Ghabach B, Neerukonda L, Narra K, et al.
BMC Cancer
. 2022 Jun;
22(1):593.
PMID: 35641921
Background: Prior studies reported survival benefits from early initiation of adjuvant chemotherapy for stage III colon cancer, but this evidence was derived from studies that may be sensitive to time-related...
6.
Rich P, Mitchell R, Schaefer E, Walker P, Dubay J, Boyd J, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34706885
Purpose: Immune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host...
7.
Lu Y, Gehr A, Narra K, Lingam A, Ghabach B, Meadows R, et al.
Ann Epidemiol
. 2021 Oct;
65:31-37.
PMID: 34601096
Purpose: We aimed to assess whether differences in the distributions of prognostic factors explain reported mortality disparities between urban safety-net and Surveillance, Epidemiology, and End Results (SEER) cancer populations. Methods:...
8.
Sridhar S, Sharma I, Sankpal U, Ghabach B, Narra K, Neerukonda L, et al.
Crit Rev Oncog
. 2020 Sep;
25(1):47-55.
PMID: 32865910
Liver cancer is the 6th leading cause of cancer related deaths in the US even though it ranks 14th in incidence. More men are diagnosed with liver cancer than women,...
9.
Lambring C, Ghabach B, Narra K, Basha R
Crit Rev Oncog
. 2020 Sep;
25(1):31-46.
PMID: 32865909
Liver cancer is a particularly aggressive group of malignancies with historically low survival rates. Despite advancements in cancer treatments in general in the last few decades, incidence and mortality have...
10.
Barnett T, Lu Y, Gehr A, Ghabach B, Ojha R
BMC Cancer
. 2020 Aug;
20(1):726.
PMID: 32758159
Background: We aimed to estimate the effects of smoking cessation on survival among people diagnosed with cancer. Methods: We used data from a Comprehensive Community Cancer Program that is part...